Aarey Drugs & Pharmaceuticals Limited Overview
Aarey Drugs & Pharmaceuticals is a family-controlled Indian micro-cap. It runs two businesses side by side: a small bulk-drug (API) and intermediate manufacturing operation at MIDC Tarapur in Maharashtra, and a much larger trading operation as an importer and dealer of solvents and chemicals. Its manufactured products are commodity molecules: Metronidazole, Metronidazole Benzoate, the nitroimidazole intermediate 2-Methyl-5-Nitroimidazole (MNI), Mono- and Di-Methyl Urea, Metformin and Uracil. Customers are domestic formulation manufacturers and pharmaceutical merchant exporters. Revenue is substantial for its size (INR 4,723 M in FY2026), but economics are thin. Gross margins of 2.5–5% and net margins below 1.4% are consistent with a business that resembles a chemical distributor more than an API innovator. Since 2023 the company has raised equity repeatedly through promoter and non-promoter preferential issues and warrants. Debt has risen to finance working capital and a stepped-up FY2026 capital-expenditure programme. The equity has re-rated sharply, but earnings have not.
Company's own description
Aarey's statutory letterhead describes it in two parts: a manufacturer of bulk drugs, and an importer of (or dealer in) solvents and chemicals. Its quarterly results define its sole segment as manufacturing and trading of drugs and pharmaceuticals and activities allied to them. Corporate summaries derived from its annual reports describe it as a manufacturer and supplier of:
-
pharmaceutical raw materials and chemicals;
-
pharmaceutical ingredients and APIs;
-
food colours and flavours.
The company states that its products meet Indian, British, Chinese and US pharmacopoeial standards (IP/BP/CP/USP). It says it serves pharmaceutical formulation manufacturers and pharmaceutical merchant exporters. Source: company summaries on ICICI Direct, Kotak Securities and IIFL derived from annual reports; NSE filing letterheads 2023–2026; Q2 FY2026 results notes.
Business model and revenue model
The company earns revenue in two ways.
-
Manufactured APIs and intermediates. These are batch-chemistry products from the Tarapur plant: nitroimidazoles (MNI → Metronidazole → Metronidazole Benzoate), methyl ureas, Metformin and Uracil. They are sold business-to-business, on spot or short-term contracts, at commodity prices.
-
Traded solvents and chemicals. Imported or domestically sourced solvents and chemicals are resold to industrial and pharmaceutical users. This line drives the scale of the top line but carries very low unit margins.
The company does not disclose how revenue splits between manufacturing and trading. The financial profile strongly suggests trading dominates:
Margins: cost of revenue was 96–97.5% of sales in FY2022–FY2026 (S&P Global data via StockAnalysis).
Asset intensity: fixed assets were only about INR 260 M in FY2026 (Screener) against INR 4.7 bn of revenue, an asset-light turnover profile.
Lumpiness: quarterly revenue swings widely, from INR 510 M in Q1 FY2024 to INR 2,104 M in Q4 FY2024, and from INR 1,895 M in Q4 FY2026 to INR 446 M in Q1 FY2027. This pattern is typical of opportunistic bulk trading.
Value-chain position
Aarey sits in the middle of the pharmaceutical value chain. It buys basic chemical inputs, typically petrochemical and agrochemical derivatives, and processes some into intermediates (MNI) and finished APIs (Metronidazole, Metronidazole Benzoate). It sells these to formulators, who make tablets, suspensions and veterinary products. It does no formulation itself and has no branded consumer presence. In its trading activity it acts as a distributor between chemical producers (often importers' overseas suppliers) and Indian users.
Customer types and end-markets
| Customer type | Description | Evidence |
|---|---|---|
| Domestic formulation manufacturers | Tablet and suspension makers using Metronidazole, Metronidazole Benzoate and Metformin | Company description (Screener, IIFL) |
| Pharmaceutical merchant exporters | Traders who export APIs to regulated and semi-regulated markets | Company description |
| Chemical and industrial users | Buyers of traded solvents and chemicals, and of methyl ureas, which are used in pharma, agrochemical and caffeine/theophylline chemistry | Letterhead ("importers of solvents & chemicals") |
| Food industry | Food colours and flavours supply | Annual report summaries (scale not disclosed) |
End-markets served:
Anti-infectives: Metronidazole for anaerobic and protozoal infections, used in human and veterinary medicine.
Anti-diabetics: Metformin.
Oncology and antiviral building blocks: Uracil is a pyrimidine intermediate.
General industrial chemicals: ### Independent characterisation
The most accurate description is a chemical trading house with an attached small API plant, not a pharmaceutical company in the R&D sense. Its competitive variables are three: working-capital access (bank lines plus promoter equity), sourcing relationships, and price. Product differentiation is not one of them. Returns reflect this. Screener reports ROE of 2.75% and ROCE of 5.58% on FY2026 data, and a three-year average ROE of about 3.1%. Both are well below the cost of capital. The FY2026 capex step-up (INR 124 M, against INR 7–52 M in prior years) is the clearest recent sign that management may be trying to raise the manufacturing share of the mix. The company has not publicly described what the capex funds.
Strategy
Stated strategy
Aarey publishes no investor presentation, holds no investor days, and gives no medium-term targets or guidance. Its strategy has to be inferred from three sources: the stated objects of its preferential issues, which point to funding working capital, business growth and general corporate purposes; its capital allocation; and historical annual-report themes. The objects text was amended by the 27 December 2024 corrigendum, but the detailed allocation is not reproduced in the sources reviewed.
Recurring themes, as paraphrased from company summaries:
-
Backward integration and plant upgrading at Tarapur to international standards (2009, 2014-15).
-
Portfolio extension into adjacent bulk molecules (methyl ureas in 2016; Metformin and Uracil in 2017–19).
-
Pharmacopoeial compliance (IP/BP/CP/USP) to qualify as a supplier to formulators and merchant exporters.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Date | Initiative | Detail | Status |
|---|---|---|---|
| Dec 2024 – May 2025 | Equity raise via 5.0 M convertible warrants | EOGM 2 Jan 2025; allotment 23 May 2025; 25% upfront; 18-month conversion window | 3.52 M converted by Oct 2026 (see Section 11); 1.48 M outstanding |
| FY2026 | Capex step-up | Capital expenditure of INR 124.1 M, versus INR 52.0 M in FY2025 and INR 7.2 M in FY2024; net block roughly INR 160 M → INR 260 M | Spent; the project's purpose has not been publicly detailed |
| Aug – Oct 2026 | Promoter capital infusion | Promoter-group warrant conversion of 2.52 M shares, at a balance of 75% of the issue price | Completed |
| Ongoing | Compliance remediation | Follows the exchange fine (Feb 2026) and the secretarial-audit observations (May 2026) | — |
ESG and cost programmes
None disclosed. There are no stated emissions targets, cost-reduction programmes, or sustainability commitments.
Medium-term financial targets
| Target type | Disclosure |
|---|---|
| Revenue guidance | — |
| Margin targets | — |
| Capex plan | — |
| Leverage targets | — |
| Dividend policy | No dividend paid in the period reviewed |
Products & Services
All products sit within the single "Drugs and Pharmaceuticals" segment. The company does not publish a price list, capacity by product, or product-level revenue. Launch years come from annual-report summaries.
Flagship offerings. The nitroimidazole chain (MNI → Metronidazole → Metronidazole Benzoate) is the company's historic identity and its only evident backward integration. Metformin is its highest-volume end-market by global demand. Aarey's share of national Metformin output is not disclosed and is likely small.
Unknowns. The sources reviewed do not disclose installed capacity by product, regulatory filings (US DMFs, CEPs, WHO-GMP certification), or new molecules under development. The company has not announced any new product launch since the Metformin/Uracil additions in FY2018–19.
Product Portfolio
| # | Product | Category | Description & use | Specification / standard | Target customer | Launch / production start | Pricing model |
|---|---|---|---|---|---|---|---|
| 1 | Metronidazole | API (nitroimidazole antibiotic / antiprotozoal) | Active ingredient for formulations treating anaerobic bacterial and protozoal infections (e.g., amoebiasis, trichomoniasis, giardiasis); also used in veterinary medicine | IP/BP/USP grade (company claim) | Domestic formulators; merchant exporters | Core legacy product (exact year not disclosed) | Commodity spot/contract pricing; not disclosed |
| 2 | Metronidazole Benzoate | API (ester prodrug of Metronidazole) | Taste-masked form used mainly in paediatric oral suspensions | IP/BP grade (company claim) | Liquid-formulation makers | Legacy product (year not disclosed) | — |
| 3 | 2-Methyl-5-Nitroimidazole (MNI) | Key intermediate | Precursor for Metronidazole and other nitroimidazoles (Tinidazole, Ornidazole, Secnidazole); supports in-house backward integration and is sold to third parties | Industrial/pharma grade | In-house use; other nitroimidazole API makers | Legacy product | — |
| 4 | Mono Methyl Urea (MMU) | Chemical intermediate | Intermediate used in pharmaceutical (e.g., xanthine/caffeine chemistry) and agrochemical synthesis | — | Pharma/agrochem manufacturers | June 2016 | — |
| 5 | Di Methyl Urea (DMU) | Chemical intermediate | Intermediate for caffeine, theophylline and other syntheses; also used in textile and other chemical applications | — | Chemical/pharma manufacturers | June 2016 | — |
| 6 | Metformin (Hydrochloride) | API (biguanide anti-diabetic) | First-line oral therapy for type 2 diabetes; very high-volume generic API | IP/BP/USP grade (company claim) | Formulators of diabetes therapies | FY2017-18 / FY2018-19 | — |
| 7 | Uracil | Intermediate (pyrimidine base) | Building block for pyrimidine-based APIs (e.g., 5-Fluorouracil, antivirals) | — | API manufacturers | FY2017-18 / FY2018-19 | — |
| 8 | Traded solvents & chemicals | Trading | Imported and domestic solvents and industrial chemicals resold to industrial users | Not applicable | Pharma, chemical and industrial buyers | Ongoing | Cost-plus trading margin (inferred) |
| 9 | Food colours & flavours | Trading / supply | Referenced in corporate summaries as part of the supply portfolio | — | Food processors | — | — |
“—” = not publicly disclosed.
Financial Narrative
Primary source for the five-year series: S&P Global Market Intelligence data published by StockAnalysis (last updated 14 August 2026), built from audited annual statements filed with BSE/NSE. It is cross-checked against Screener.in (INR crore, rounded) and NSE result filings. Where the two disagree, both are shown.
Margins
Revenue CAGR
Commentary on the income statement. Three patterns stand out.
-
Revenue has plateaued. Revenue peaked in FY2022 at INR 4.93 bn, when pandemic-era API and solvent prices were high and the top line grew 40%. It fell for two years to INR 4.03 bn in FY2024. It recovered to INR 4.74 bn in FY2025 on strong Q1–Q3 trading volumes, then held flat in FY2026. The five-year growth rate of about 6% per year is driven mainly by the base effect from FY2021 (INR 3.48 bn).
-
Gross margin is very low and volatile. It moved between 2.5% and 5.1% with no trend. The FY2025 trough at 2.50% coincided with the highest revenue since FY2022, which suggests incremental volume came from lower-margin trading. The FY2026 recovery to 3.74%, alongside flat revenue, points to a richer mix or better spreads.
-
Other income matters more than operations. Other income rose from about INR 30 M to INR 100 M (FY2025). It has accounted for a growing and at times dominant share of pre-tax profit: in FY2025 pre-tax income was INR 61 M against operating EBITDA of about INR 30 M. Screener flags INR 61 M of other income in FY2026, and INR 98–106 M on a trailing basis during FY2026. The composition is not broken down in the sources reviewed; S&P classifies INR 56 M of FY2025 as interest and investment income. Core operations barely cover interest costs: FY2026 operating income of INR 43 M was below interest expense of INR 50 M.
-
SG&A jumped in FY2026. It rose from INR 16.7 M to INR 56.6 M. The cause is not disclosed; possible drivers include higher employee costs, professional fees linked to the capital-raising, and compliance costs.
Balance sheet
Notes on the balance sheet
Debt and cash: from S&P via StockAnalysis. At 30 June 2026 debt was INR 607.5 M and cash INR 34.0 M, giving net debt of INR 573.5 M.
Simply Wall St snapshot: (most recent balance sheet, likely 30 September 2025):
Equity derivation: book value per share (Screener) of INR 48.8 at Mar 2025 and INR 53.0 at Mar 2026, each multiplied by 28.354 M shares.
Debt maturity: the short- versus long-term split is not separately disclosed in the sources reviewed. Long-term liabilities of only INR 23 M imply that almost all borrowings are short-term working-capital facilities.
Fixed assets: Screener row values of INR 14 crore (FY2022) to INR 26 crore (FY2026) are interpreted as net block, consistent with the FY2026 capex of INR 124 M.
Working capital: about INR 1,200 M (short-term assets of INR 2.6 bn less short-term liabilities of INR 1.4 bn, Simply Wall St). Annual year-end figures are not available.
Commentary on the balance sheet. The balance sheet is dominated by working capital, mainly receivables and inventory. Total debt quadrupled between FY2022 and FY2026, from INR 142 M to INR 583 M, even though the company raised about INR 100 M of equity in March 2024 and about INR 80 M of warrant subscription money in May 2025. Net debt rose by about INR 146 M in FY2026 alone, funding the INR 124 M capex and working capital. There is no goodwill, which is consistent with no acquisitions.
Cash flow
Commentary on cash flow. Operating cash flow was negative or near zero in FY2022–FY2024 as working capital absorbed cash. Cash conversion improved markedly in FY2025 and FY2026, with OCF of about INR 100 M in each year, well above net income of about INR 40 M. That suggests some release of receivables; Screener notes debtor days improving from 146 to 103. FY2026 capex of INR 124 M was more than double the prior five-year cumulative total excluding FY2025, and turned FCF negative again. No dividends or buybacks were paid in any year. Screener notes the company pays no dividend despite reporting profits, and the last corporate action of that kind was a bonus issue in 2012.
Ratios
Notes: - ROE and ROCE are from Screener's FY2025 and FY2026 snapshots. Screener's three-year average ROE is 3.31% (FY2023–25) and 3.13% (FY2024–26).
- The current ratio of 1.86 uses the Simply Wall St snapshot (INR 2.6 bn ÷ 1.4 bn), not a strict FY-end figure.
Debt/equity is total debt divided by derived equity: - Net debt/EBITDA uses rounded Screener EBITDA, so treat it as indicative.
- Simply Wall St reports an interest-coverage ratio of −1.9x on its own EBIT definition. The two methods conflict; the operating-income method above is shown for consistency.
Commentary on ratios. Leverage relative to equity is moderate (0.39x debt/equity in FY2026). Leverage relative to operating earnings is high and rising: interest coverage on operating income fell below 1x in FY2026, and pre-tax profits depend on other income. The cash conversion cycle widened from 26 days (FY2022) to 68–80 days (FY2023–FY2026), the main reason borrowing rose faster than revenue. Returns of about 3% ROE are far below any reasonable cost of equity for an Indian micro-cap (13–15%). On these numbers the business has not created economic value over the period reviewed.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Drugs & Pharmaceuticals segment revenue (INR Mn) | 4,026 | 4,739 | 4,723 |
Segment pre-tax income (INR Mn) | 53.4 | 61.0 | 54.1 |
Segment pre-tax margin (%) | 1.33 | 1.29 | 1.15 |
Segment revenue YoY growth (%) | -3.91 | 17.73 | -0.35 |
Contribution to total revenue (%) | 100 | 100 | 100 |
Segment Revenue
| Metric | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
FY2024 revenue (INR Mn) | 510 | 578 | 765 | 2,104 |
FY2025 revenue (INR Mn) | 1,269 | 1,052 | 1,340 | 1,081 |
FY2026 revenue (INR Mn) | 1,020 | 840 | 960 | 1,895 |
FY2027 revenue (INR Mn) | 446 | — | — | — |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (INR Mn) | 4,929 | 4,190 | 4,026 | 4,739 | 4,723 |
Revenue growth YoY (%) | 40.27 | -15.01 | -3.91 | 17.73 | -0.35 |
Cost of revenue (INR Mn) | 4,721 | 4,039 | 3,819 | 4,621 | 4,545 |
Gross profit (INR Mn) | 208.5 | 150.9 | 206.4 | 118.2 | 177.6 |
SG&A (INR Mn) | 20.5 | 15.5 | 14.2 | 16.7 | 56.6 |
Other operating expenses (INR Mn) | 67.9 | 52.7 | 77.5 | 30.9 | 49.3 |
Operating income (INR Mn) | 100.3 | 66.9 | 97.7 | 51.2 | 43.2 |
EBITDA excl. other income (INR Mn, Screener, rounded) | 110 | 80 | 40 | 30 | 70 |
Interest expense (INR Mn) | 18.1 | 25.4 | 42.0 | 35.4 | 50.0 |
Other income (INR Mn, Screener, rounded) | 30 | 30 | 70 | 100 | 60 |
Pre-tax income (INR Mn) | 100.4 | 60.1 | 53.4 | 61.0 | 54.1 |
Income tax (INR Mn) | 34.8 | 22.4 | 6.6 | 20.8 | 14.5 |
Net income (INR Mn) | 65.6 | 37.7 | 46.8 | 40.2 | 39.7 |
EPS basic (INR, S&P) | 2.72 | 1.48 | 1.84 | 1.41 | 1.39 |
EPS (INR, Screener) | 2.58 | 1.49 | 1.67 | 1.42 | 1.40 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Gross margin (%) | 4.23 | 3.60 | 5.13 | 2.50 | 3.74 |
Operating margin (%) | 2.03 | 1.60 | 2.43 | 1.08 | 1.22 |
EBITDA margin excl. OI (%, Screener-derived) | 2.2 | 1.9 | 1.0 | 0.6 | 1.5 |
Pre-tax margin (%) | 2.04 | 1.43 | 1.33 | 1.29 | 1.15 |
Net margin (%) | 1.33 | 0.90 | 1.16 | 0.85 | 0.84 |
Effective tax rate (%) | 34.7 | 37.3 | 12.3 | 34.1 | 26.7 |
Valuation Snapshot
| Metric | Value |
|---|---|
Revenue CAGR FY2022–FY2026, 4 years (%) | -1.1 |
Revenue CAGR FY2021–FY2026, 5 years (%, Screener) | 6.27 |
Net income CAGR FY2022–FY2026 (%) | -11.8 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash & short-term investments (INR Mn) | 1.9 | 11.2 | 28.9 | 32.3 | 34.0 |
Total debt (INR Mn) | 141.6 | 377.2 | 313.5 | 435.5 | 582.9 |
Net debt (INR Mn) | 139.7 | 365.9 | 284.6 | 403.2 | 549.0 |
Shareholders' equity (INR Mn, derived from Screener book value per share) | — | — | — | 1,384 | 1,503 |
Total assets (INR Mn) | — | — | — | 2,940 | — |
Fixed assets / net block (INR Mn, Screener, rounded) | 140 | 140 | 130 | 160 | 260 |
Goodwill & intangibles (INR Mn) | 0 | 0 | 0 | 0 | 0 |
Financial Analysis
| Item | INR Mn |
|---|---|
Total equity | 1,490 |
Total debt | 569.6 |
Debt-to-equity | 38.3% |
Total assets | 2,940 |
Total liabilities | 1,450 |
Short-term assets | 2,600 |
Short-term liabilities | 1,400 |
Long-term liabilities | 23.0 |
Cash & short-term investments | 81.9 |
Cash Flow and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (INR Mn) | 5.0 | -12.8 | -29.9 | 103.0 | 101.4 |
Capital expenditure (INR Mn) | -22.0 | -10.4 | -7.2 | -52.0 | -124.1 |
Free cash flow (INR Mn) | -17.0 | -23.3 | -37.2 | 51.0 | -22.7 |
FCF margin (%) | -0.34 | -0.56 | -0.92 | 1.07 | -0.48 |
Dividends paid (INR Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (INR Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%) | — | — | — | 2.96 | 2.75 |
ROCE (%, Screener) | — | — | — | 6.38 | 5.58 |
ROA (%, net income / total assets) | — | — | — | 1.4 | — |
Current ratio (x) | — | — | — | 1.86 | — |
Debt / equity (x) | — | — | — | 0.31 | 0.39 |
Net debt / EBITDA excl. OI (x) | 1.3 | 4.6 | 7.1 | 13.4 | 7.8 |
Interest coverage, operating income / interest (x) | 5.53 | 2.63 | 2.33 | 1.44 | 0.86 |
Asset turnover (x) | — | — | — | 1.61 | — |
Inventory days (Screener) | 11 | 26 | 33 | 36 | 33 |
Cash conversion cycle, days (Screener) | 26 | 76 | 80 | 58 | 68 |
P/E at fiscal year-end (x, S&P) | 16.03 | 15.93 | 26.76 | 23.42 | 36.49 |
P/S at fiscal year-end (x, S&P) | 0.21 | 0.14 | 0.31 | 0.20 | 0.31 |
Revenue by Region
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total revenue (INR Mn) | 4,026 | 4,739 | 4,723 |
Per-Share Data and Market Valuation
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Implied FY-end share price (INR, P/E × EPS, S&P) | 43.6 | 23.6 | 49.2 | 33.0 | 50.7 |
Implied FY-end market cap (INR Mn, P/S × revenue, S&P) | 1,035 | 587 | 1,248 | 948 | 1,464 |
P/E at FY-end (x) | 16.03 | 15.93 | 26.76 | 23.42 | 36.49 |
P/S at FY-end (x) | 0.21 | 0.14 | 0.31 | 0.20 | 0.31 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Share Price & Returns
| Period | Approximate return | Basis |
|---|---|---|
FY2027 to date (31 Mar 2026 → 16 Oct 2026) | About +120% | INR ~50.7 to INR ~112 |
1 year (Oct 2025 → Oct 2026) | About +55–65% | INR ~67–70 (Screener, Nov 2025) to INR ~110; 52-week low INR 50.31 |
Valuation Multiples
| Multiple | Aarey Drugs | Basis |
|---|---|---|
Share price (INR) | ~110–112 | 52-week high INR 112.15 (16 Oct 2026) |
Market cap (INR Mn) | ~3,500–3,570 | 31.87 M shares |
Trailing P/E (x) | ~81–88 | StockAnalysis 81.16 at INR 106.80 (6 Oct 2026); TTM EPS INR 1.27 |
P/B (x) | ~2.0–2.1 | BVPS INR 53.0 (Mar 2026); diluted book value rises after conversions |
EV/Sales (x) | ~0.98 | EV of about INR 4,080 M (market cap plus net debt of INR 573.5 M) ÷ TTM revenue of INR 4,147 M |
EV/EBITDA (x) | ~55–60 | EV ÷ FY2026 EBITDA excluding OI of about INR 70 M (TTM likely lower given the Q1 FY2027 core loss) |
P/S (x) | 0.71 | StockAnalysis, 6 Oct 2026 |
Capital Markets
| Item | Status |
|---|---|
Sell-side coverage | Simply Wall St lists 1 analyst covering, with 0 estimates submitted. There is no published consensus. |
Quantitative ratings | MarketsMojo: "Strong Sell" (April–May 2026), then "Sell" (4 and 15 October 2026) |
Dividend policy | No dividend paid in FY2022–FY2026; no formal policy disclosed (not mandatory outside the top 1,000 companies) |
Credit ratings: Moody's / S&P / Fitch | None (not rated) |
Domestic rating history | SMERA/Acuité BBB-/Stable on INR 150 M of bank facilities (4 Aug 2017); ICRA rating suspended (19 Jun 2017); CRISIL rating suspended. A current rating is not publicly disclosed. |
Debt maturity profile | Not disclosed. Long-term liabilities of only about INR 23 M imply that nearly all of the INR 583–607 M of borrowings are short-term working-capital facilities, renewed annually. |
Analyst Conclusions
Management guidance and consensus
| Item | Status |
|---|---|
| Management revenue / earnings guidance | None issued |
| Medium-term targets | None issued |
| Consensus growth expectations | None (no analyst estimates) |
| Next scheduled events | Q2 FY2027 results (quarter ending 30 Sep 2026), due by mid-November 2026 under LODR timelines; expiry of the remaining 1.48 M warrants about 22–23 Nov 2026 (18 months from the 23 May 2025 allotment) |
Bull case
-
Deleveraging from fresh equity. Warrant conversions brought in about INR 170 M in August–October 2026, with up to about INR 71 M more available. Against net debt of INR 573.5 M, this could cut net debt by 30–40% and reduce an interest bill of about INR 50 M a year. Interest is currently the single largest drag between gross profit and PBT.
-
Payoff from the FY2026 capex. The INR 124 M of capex roughly doubled the net block (INR 160 M → INR 260 M). FY2026 gross margin rose from 2.50% to 3.74% on flat revenue. If the new capacity shifts the mix toward manufactured APIs, margins could move toward the FY2024 peak of 5.1% or above.
-
Promoter alignment. The promoter group converted 2.52 M warrants at an effective INR 63.80 per share. That puts fresh promoter capital at risk and signals confidence. A strong Q4 FY2026 (revenue +75% YoY, PAT +232% YoY) shows the operating leverage available when trading volumes are high.
Bear case
-
Earnings quality is poor and worsening. Core operating income in FY2026 (INR 43 M) did not cover interest (INR 50 M). Q1 FY2027 showed a core pre-tax loss of about INR 12 M on revenue down 56% YoY. Reported profits depend on other income whose composition is not disclosed.
-
Valuation has detached from fundamentals. At about 80–90x trailing earnings, about 2x book and 55–60x EV/EBITDA, the market is pricing a business with ROE of about 3% and flat revenue as though it were a growth API franchise. Repeated circuit locks in 2026 show the speculative, illiquid nature of the price.
-
Governance and disclosure deficits. An exchange fine for related-party disclosure lapses, a secretarial audit flagging multiple SEBI non-compliances, unresolved discrepancies in share-count and promoter-holding disclosures, family concentration in key managerial roles, and no investor communication all raise the discount investors should apply.
Key catalysts and monitorables (next 12 months)
| Monitorable | Why it matters |
|---|---|
| Q2 FY2027 results (by mid-Nov 2026) | Whether the Q1 revenue collapse was a timing effect or a trend |
| Exercise or lapse of the 1.48 M outstanding warrants (about 22–23 Nov 2026) | Further capital of up to about INR 71 M versus forfeiture of the 25% upfront money |
| Use of warrant proceeds: debt repayment vs working capital vs capex | Path of net debt from INR 573.5 M and of interest coverage |
| Disclosure of what the FY2026 capex funded, and commissioning | Mix shift toward manufacturing and margin expansion |
| Composition of other income | Sustainability of reported profits |
| Promoter holding after conversions (Sep 2026 and Dec 2026 patterns) | Reconciles the 44.80% vs 39.06% discrepancy; shows promoter direction |
| Further exchange or SEBI actions | Escalation risk following the FY2026 compliance findings |
| Tax litigation developments (key audit matter) | Contingent cash-outflow risk |
| FY2026 annual report notes (geography, RPTs, contingent liabilities) | Fills material disclosure gaps |
Analyst verdict
Aarey Drugs & Pharmaceuticals is best understood as a promoter-run chemical trading house with a modest API plant attached, not as a pharmaceutical growth company. Over five fiscal years revenue has gone nowhere: INR 4.93 bn in FY2022 and INR 4.72 bn in FY2026, a compound decline of about 1% a year. Net income fell from INR 65.6 M to INR 39.7 M. Margins are among the thinnest in listed Indian pharma: gross margin of 3.7% and net margin of 0.8% in FY2026. Returns on equity of about 3% have consistently fallen short of any plausible cost of capital.
Recent signals point in both directions. In its favour, management has raised meaningful equity, the promoters have put their own money into warrant conversions, operating cash flow has turned solidly positive (about INR 100 M in each of FY2025 and FY2026), and FY2026 capex more than doubled the asset base. These are the ingredients a turnaround would need. Against that, the Q1 FY2027 results showed revenue down 56% and a core operating loss. Pre-tax profit depends on other income. Operating income no longer covers interest. Governance hygiene has slipped, as shown by the related-party disclosure fine and the secretarial-audit findings.
The equity market has priced the optimistic reading. The stock more than doubled during FY2027 to an all-time high of about INR 112, roughly 85x trailing earnings. Nothing in the disclosed numbers yet supports that multiple. Until the company shows several quarters of higher manufacturing-led gross margins, interest coverage restored above 2x, and clearer disclosure on capex, other income and related parties, the risk-reward appears unfavourable. Aarey merits monitoring as a possible turnaround, not underwriting as an investment. Our overall assessment is Negative / High Risk, with Q2 FY2027 results and the November 2026 warrant expiry as the immediate tests.
Source register (principal documents)
| Source | Type | Content used |
|---|---|---|
| NSE filing, 30 May 2026: Audited standalone results Q4 and FY2026 | Primary | FY2026 results, audit opinion, letterhead addresses |
| NSE integrated filing (iXBRL), 14 Aug 2026: Q1 FY2027 | Primary | Q1 FY2027 revenue, PBT, PAT; segment definition |
| NSE integrated filing (iXBRL), 14 Nov 2025: Q2 FY2026 | Primary | Single-segment disclosure; ISIN and identifiers |
| NSE governance filing (iXBRL), 30 Apr 2026 | Primary | Corporate governance report applicability |
| NSE filings: 23 May 2025 warrant allotment; 6 Aug 2026 conversion; 12 Feb 2026 fine; 3–4 Sep 2025 board outcomes; 27 Dec 2024 corrigendum | Primary | Capital-markets register, governance events |
| BSE filings: preferential-issue notices 2023–2024; allotment intimation (Mar 2024); 2022 board outcomes; Annual Report 2019-20 | Primary | History, capital raises, auditor appointment, addresses |
| Acuité (SMERA) rating rationale, 4 Aug 2017 | Primary (rating agency) | Rating history, FY2017 financials, plant upgrade |
| S&P Global Market Intelligence via StockAnalysis (updated 14 Aug 2026) | Aggregator | Five-year income statement, balance sheet, cash flow, margins, multiples |
| Screener.in | Aggregator | Rounded financials, ratios, filing summaries |
| MarketsMojo; Simply Wall St; Upstox; Angel One; Torus Digital; Bajaj Finserv; Emkay; Equitymaster; Vogue/BFSL; Fyers; IndMoney; Tickertape; TipRanks; ScanX; Whalesbook; Univest; IIFL; ICICI Direct; Kotak Securities | Aggregators / news | Quarterly series, shareholding, management, price action, ratings, company background |
All figures are standalone. Discrepancies between sources are noted where they occur.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Role | Tenure | Background / notes | Compensation (latest disclosed) |
|---|---|---|---|---|
Mihir Rajesh Ghatalia | Managing Director (DIN 00581005); de facto CEO | MD since December 2009 (Simply Wall St); signed as MD in 2022 filings | B.E. (engineering graduate); also Executive Director at Worth Investment & Trading Company Ltd; promoter | INR 1.07 M total yearly compensation, 56% salary and 44% bonus (Simply Wall St, FY2025 basis) |
Nimit Rajesh Ghatalia | Director (DIN 07069841); signs most exchange filings | — | Promoter-family member; also linked to promoter entity Nimit Impex | — |
Mira Mihir Ghatalia | Chief Financial Officer (per Vogue/BFSL company information page) | — | — | — |
Kailash Chand Jethlia | Company Secretary & Compliance Officer | — | — | — |
Rajesh Pranlal Ghatalia | Promoter (0.01% holding); patriarch of the promoter family | — | — | — |
Independent directors | — | — | Simply Wall St reports an average board tenure of 5.7 years and average management tenure of 5.4 years | Sitting fees not disclosed |
“—” = not publicly disclosed.
Governance Overview
| Governance attribute | Status |
|---|---|
Risk management committee | Not applicable (company is below the top-1,000 market-cap threshold; per the FY2026 governance filing dated 30 April 2026) |
Corporate governance compliance report | Filed quarterly (Annexure I, SEBI circular of 31 December 2024) |
Board & Management Changes
| Date | Event |
|---|---|
3 Sep 2025 | Board recommends reappointment of statutory auditor Motilal & Associates for a second five-year term (FY2025-26 to FY2029-30) and appoints a secretarial auditor for FY2025-26 onward |
29 Sep 2025 | 35th AGM: reappointment of a director retiring by rotation and the auditors; related-party transaction cap of INR 20 M approved (per Screener summary) |
30 Sep 2026 | 36th AGM held by video conference |
Shareholding Trend
| Holder category | Mar-2023 | Mar-2024 | Mar-2025 | Sep-2025 | Dec-2025 | Mar-2026 |
|---|---|---|---|---|---|---|
Promoter & promoter group (%) | 50.04 | 45.28 | 44.80 | 44.80 | 39.06 | 37.71 |
FIIs / FPIs (%) | 3.92 | 3.40 | 2.34 | 1.13 | 3.86 | — |
Domestic institutions incl. mutual funds (%) | 0 | 0 | 0 | 0 | 0 | 0 |
Retail and others (%) | 46.04 | 51.32 | 52.86 | 54.07 | 57.09 | — |
Major Shareholders
| Rank | Holder | Category | Shares | Stake (%) |
|---|---|---|---|---|
| 1 | Bina Rajesh Ghatalia | Promoter | 4,003,584 | 14.12 |
| 2 | Mihir Rajesh Ghatalia | Promoter | 2,835,888 | 10.00 |
| 3 | Nimit Impex | Promoter group | 2,010,000 | 7.09 |
| 4 | Nimit Rajesh Ghatalia | Promoter | 1,150,000 | 4.06 |
| 5 | Elysian Wealth Fund | Public (FPI) | 750,000 | 2.65 |
| 6 | Mira Mihir Ghatalia | Promoter | 690,000 | 2.43 |
| 7 | Krishnamurthy C G | Public | 500,000 | 1.76 |
| 8 | Chetan Kiritbhai Mehta | Public | 450,000 | 1.59 |
| 9 | Nishith Atulbhai Shah | Public | 402,473 | 1.42 |
| 10 | Archana Pramod Wani | Public | 400,000 | 1.41 |
| 11 | Suraj Tradelinks | Promoter group | 381,336 | 1.34 |
| 12 | Resonance Opportunities Fund | Public (FPI) | 299,000 | 1.05 |
Competitive Landscape
Key Competitors
| # | Competitor | Overlap with Aarey | Relative positioning |
|---|---|---|---|
| 1 | Aarti Drugs Ltd | Metronidazole (a leading global producer), Metformin, other anti-infective and anti-diabetic APIs | Far larger, integrated; market cap about INR 29 bn (Vogue/BFSL peer table, early 2026) |
| 2 | Aarti Pharmalabs Ltd | APIs, intermediates, xanthine derivatives (caffeine chain, which uses methyl ureas) | Market cap about INR 54 bn (Vogue/BFSL peer table) |
| 3 | Granules India Ltd | Metformin (among the largest global producers) | Large-scale, regulated-market focus |
| 4 | Harman Finochem Ltd (unlisted) | Metformin | Specialist Metformin producer |
| 5 | Denis Chem Lab Ltd | Pharma products; named by MarketsMojo as a peer | Similar micro/small-cap scale |
| 6 | Unique Chemicals / Unique Pharmaceutical Laboratories (J.B. Chemicals group) | Nitroimidazoles | Established nitroimidazole maker |
| 7 | Bajaj Healthcare Ltd | Bulk APIs and intermediates | Small-cap API peer |
| 8 | Kopran Ltd | APIs (anti-infectives) | Small-cap API peer with export focus |
| 9 | Supriya Lifescience Ltd | Niche APIs | Higher-margin, regulated-market focus |
| 10 | Chinese nitroimidazole and Metformin producers (multiple) | Price-setting import competition in commodity APIs and intermediates | Scale and cost leaders |
| 11 | Chemical distributors and traders (numerous unlisted) | Solvent and chemical trading | Fragmented; competition is on credit terms and price |
Peer Comparison FY2026
| Metric | Aarey Drugs | Aarti Drugs | Aarti Pharmalabs |
|---|---|---|---|
FY2026 revenue (INR Mn) | 4,723 | — | — |
Revenue growth FY2026 (%) | -0.35 | — | — |
Gross margin FY2026 (%) | 3.74 | — | — |
Net margin FY2026 (%) | 0.84 | — | — |
Market cap (INR Mn) | ~3500 (Oct 2026) | ~29184 (early 2026, Vogue/BFSL) | ~53665 (early 2026, Vogue/BFSL) |



